{"entity":{"id":"nct04576156","kind":"trial","name":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","aka":[],"tldr":"A phase 3 trial of Imetelstat in myeloproliferative neoplasms, run by Geron Corporation, active and no longer recruiting.","summary":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment is a phase 3 interventional study registered as NCT04576156 by Geron Corporation, with 327 participants enrolled, started 2021-04-12 and due to reach its primary completion in 2028-06-30. Interventions recorded: Imetelstat and Best Available Therapy (BAT).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04576156","url":"https://clinicaltrials.gov/study/NCT04576156"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["imetelstat"],"companies":["geron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04576156","phase":"3","setting":"A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor","sponsor":"Geron Corporation","enrolled":327,"outcomes":[]},"route":"/trials/nct04576156/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"imetelstat","kind":"drug","name":"Imetelstat","route":"/drugs/imetelstat/"}],"company":[{"id":"geron","kind":"company","name":"Geron Corporation","route":"/companies/geron/"}]}}